3NDX partners with Fortress Diagnostics to produce revolutionary cancer test
3N Diagnostics in Belfast has announced a partnership with Fortress Diagnostics in Antrim to manufacture its revolutionary new cancer test.
The Belfast based clinical diagnostics company 3N Diagnostics has announced that Fortress Diagnostics in Antrim will manufacture its novel and patented Avisio FOXC1 test for identifying an aggressive form of breast cancer.
To date, basal-like breast cancer (BLBC) has been extremely difficult for doctors to identify at the time of initial breast cancer diagnosis and typically can only be diagnosed between two and five years afterwards, when patients return with an unexpectedly worse course of the disease.
The Avisio FOXC1 test works through detecting a biomarker which is unique to BLBC, which helps in the diagnosis of the disease.
Dr Roberto Fagnani, CEO of 3N Diagnostics, says he was “delighted” to be entering into the manufacturing agreement with Fortress.
“This agreement will provide 3N Diagnostics with access to a highly qualified scientific team with a strong track record for the production of the new Avisio FOXC1 test for BLBC,” he said.
Dr Morteza Afrasiabi, managing director of Fortress Diagnostics added: “The Avisio FOXC1 test is a novel product, which will help revolutionise breast cancer diagnosis. We are immensely proud to be at the centre of manufacturing it for worldwide distribution.”
The new cancer test will be launched commercially throughout Europe next month.
Read the full article on todays Irish News: